Summary
Topotecan (Hycamtin®), a semisynthetic water-soluble derivative of camptothecin, is a potent inhibitor of DNA topoisomerase I in vitro and has demonstrated encouraging antitumour activity in a wide variety of tumours, including ovarian cancer and small cell lung cancer. Now approved in the US, topotecan has completed single-agent phase I testing; phase II/III trials are ongoing.
Under physiological conditions the lactone moiety of topotecan undergoes a rapid and reversible pH-dependent conversion to a carboxylated open-ring form, which lacks topoisomerase I inhibiting activity. At equilibrium at pH 7.4 the open-ring form predominates. Topotecan is stable in infusion fluids in the presence of tartaric acid (pH < 4.0), but is unstable in plasma, requiring immediate deproteinisation with cold methanol after blood sampling and storage of the extract at −30°C to preserve the lactone form.
Topotecan has been administered in phase I trials in several infusion schedules ranging from 30 minutes to 21 days. The plasma decay of topotecan concentrations usually fits a 2-compartment model. Rapid hydrolysis of topotecan lactone results in plasma carboxylate levels exceeding lactone levels as early as 45 minutes after the start of a 30-minute infusion. The peak plasma concentrations and the area under the plasma concentration-versus-time curves (AUC) show linear relationship with increasing dosages. No evidence of drug accumulation is seen with daily 30-minute infusions for 5 consecutive days.
Topotecan lactone is widely distributed into the peripheral space, with a mean volume of distribution (Vd) at steady-state of 75 L/m2. The mean total body clearance of the lactone form is 30 L/h/m2, with a mean elimination half-life (t½β) of 3 hours; renal clearance accounts for approximately 40% of the administered dose with a large interindividual variability.
The oral bioavailability of topotecan is approximately 35%. The low bioavailability may be caused by hydrolysis of topotecan lactone in the gut, yielding substantial amounts of the open-ring form, which is poorly absorbed.
Renal dysfunction may decrease topotecan plasma clearance. Creatinine clearance is significantly, but poorly, correlated with topotecan clearance. Hepatic impairment does not influence topotecan disposition.
Indices of systemic exposure (steady-state concentrations and AUC) are correlated with the extent of myelotoxicity. Sigmoidal functions adequately describe the relationships between systemic exposure and the percentage decrease in neutrophils.
Similar content being viewed by others
References
Costin D, Potmesil M. Preclinical and clinical development of camptothecins. Adv Pharmacol 1994; 29B: 51–72
Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumour inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88: 3888–90
Horwitz SB, Chang C-K, Grollman AP. Studies on camptothecin.1. Effects on nucleic acid and protein synthesis. Mol Pharmacol 1971; 7: 632–44
Kessel D, Bosmann HB, Lohr K. Camptothecin effects on DNA synthesis on murine leukaemia cells. Biochim Biophys Acta 1972; 269: 210–6
Gottlieb JA, Guarino AM, Call JB, et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium. Cancer Chemother Rep 1970; 54: 461–70
Moertel CG, Schutt AJ, Reitemeier RJ, et al. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972; 56: 95–7
Muggia FM, Creaven PJ, Hansen H, et al. Phase I clinical trial of weekly and daily treatment with camptothecin: correlation with preclinical studies. Cancer Chemother Rep 1972; 56: 515–21
Hsiang Y-H, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873–5
Hsiang Y-H, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48: 1722–6
Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046–8
Husain I. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994; 54: 539–46
McLeod HL, Douglas F, Oates M, et al. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer 1994; 59: 607–11
Jaxel C, Kohn KW, Wani MC, et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase. I. Evidence of a specific receptor site and for a relation to antitumor activity. Cancer Res 1989; 49: 1465–9
Hsiang Y-H, Liu LF, Wall ME, et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 1989; 49: 4385–9
Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989; 32: 715–20
O'Dwyer PJ, Lacreta FP, Haas NB, et al. Clinical, pharmacokinetic and biological studies of topotecan. Cancer Chemother Pharmacol 1994; 34: 46S–52S
Von Hoff DD, Burris HA III, Eckardt J, et al. Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 1994; 34: 41S-45S
Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 1994; 20: 73–96
Verweij J, ten Bokkel Huinink W, Lund B, et al. Clinical trials of topotecan in Europe. In: Potmesil M, Pinedo H, editors. Camptothecins: new anticancer agents. Boca Raton: CRC Press, 1995: 105–12
Underberg WJM, Goossen RMJ, Smith BR. Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 1990; 8: 681–3
Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992; 81: 676–84
Rosing H, Doyle E, Davies BE, et al. High-performance liquid Chromatographie determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chromotogr B Biomed Appl 1995; 668: 107–11
Beijnen JH, Smith BR, Keijer WJ, et al. High-performance liquid Chromatographie analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal 1990; 8: 789–94
Burke TG, Munshi CB, Mi Z. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 1995; 84: 518–9
Grochow LB, Rowinsky EK, Johnson R, et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 1992; 20: 706–13
Saltz L, Sirott M, Young C, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993; 85: 1499–507
Burris III HA, Awada A, Kuhn JG, et al. Phase I and pharmaconetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anticancer Drugs 1994; 5: 394–402
Van Warmerdam LJC, Creemers GJ, Rodenhuis S, et al. Pharmacokinetics and pharmacodynamics of topotecan administered at a daily times five schedule in phase II clinical trials using a limited sampling procedure. Cancer Chemother Pharmacol 1996; 38: 254–60
Van Warmerdam LJC, ten Bokkel Huinink WW, Rodenhuis S, et al. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion [published eratum appears in J Clin Oncol 1996; 14: 689]. J Clin Oncol 1995; 13: 1768–76
Tong W, Saltz L, Sirott M, et al. Rapid HPLC assay for topotecan [abstract]. Proc Am Assoc Cancer Res 1991; 32: 433
Loos WJ, Stoter G, Verweij J, et al. Sensitive high-performance liquid Chromatographie fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ringopened product (hydroxy-acid) in human plasma and urine. J Chromotogr B Biomed Appl 1996; 678: 309–15
Plaxe S, Christen R, O'Quigley J, et al. Phase I trial of intraperitoneal topotecan [abstract]. Proc Am Soc Clin Oncol 1993; 12: 140
Wall JG, Burris III HA, Von Hoff DD, et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 1992; 3: 337–45
Hasegawa K, Nishimura R, Fukuoka M, et al. Phase I and pharmacologic evaluation of topotecan on a 30 minute infusion [abstract]. Proc Am Assoc Cancer Res 1993; 34: 421
Verweij J, Lund B, Beijnen J, et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993; 4: 673–8
Haas NB, LaCreta FP, Walczak J, et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 1994; 54: 1220–6
Blaney SM, Balis FM, Cole DE, et al. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993; 53: 1032–6
Reid JM, Burch PA, Benson LM, et al. Phase I clinical and pharmacological evaluation of topotecan administered by a 24 hour continuous infusion [abstract]. Proc Am Assoc Cancer Res 1992: 33: 259
Abbruzzese JL, Madden T, Schmidt S, et al. Phase I trial of topotecan administered by 24-hour infusion without and with G-CSF [abstract]. Proc Am Assoc Cancer Res 1993; 34: 329
Stewart CF, Baker SD, Heideman RL, et al. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 1994; 12: 1946–54
Rowinsky EK, Adjei A, Donehower RC, et al. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994; 12: 2193–203
Hochster H, Liebes L, Speyer J, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994; 12: 553–9
Rowinsky EK, Grochow LB, Hendriks CB, et al. Phase I and pharmacologie study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647–56
Van Warmerdam LJC, Verweij J, Schellens JHM, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995; 35: 237–45
Herben VMM, ten Bokkel Huinink WW, Schot M, et al. Continuous infusion of low dose topotecan: a clinical pharmacologie phase II study in patients with small cell lung cancer [abstract]. Sixth Conference on DNA Topoisomerases in Therapy: 1995 Sep 6–8; Amsterdam, 77
Creemers GJ, Gerrits CHJ, Planting AST, et al. Phase II study with topotecan administered as a 21 -day continuous infusion to patients with colorectal cancer [abstract]. Eur J Cancer 1995; 31A: S146
Pratt CB, Stewart C, Santana VM, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 1994; 12: 539–43
Topotecan (SK&F 104864-A): investigator brochure. Philadelphia: Smith, Kline and French Laboratories, 1990
Cole DE, Blaney SM, Balis FM. Topotecan in physiologic fluids: depot of active drug in red blood cells. Proc Am Assoc Cancer Res 1995; 36: 363
Munshi CB, Mi Z, Burke TG. The biophysics underlying the favorable stability of the topotecan anticancer drug in human blood [abstract]. Proc Am Assoc Cancer Res 1995; 36: 444
Burke T, Mi Z, Roy D, et al. The pivotal role of albumin in determining the relative blood stabilities of camptothecin analogs presently in clinical trials [abstract]. Proc Am Soc Clin Oncol 1995; 14: 463
Baker SD, Heideman RI, Kuttesch JF, et al. CNS penetration of topotecan following continuous infusion in children with cancer. Clin Pharmacol Ther 1994; 55: 189
Van Warmerdam LJC, Rosing H, ten Bokkel Huinink WW, et al. Do topotecan concentrations in saliva reflect plasma concentrations? J Oncol Pharm Pract 1995; 1: 41–5
Scott DO, Bindra DS, Sutton SC, et al. Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats. Drug Metab Dispos 1994; 22: 438–42
Recondo G, Abbruzzese J, Newman B, et al. A phase I trial of topotecan administered by a 24-hr infusion [abstract]. Proc Am Assoc Cancer Res 1991; 32: 206
Borkowski JM, Duerr M, Donehower RC, et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 1994; 33: 493–6
Van Warmerdam LJC, Verweij J, Rosing H, et al. Limited sampling models for topotecan pharmacokinetics. Ann Oncol 1994; 5: 259–64
Leonard TB, Fish CJ, Smith B, et al. Toxicity and toxicokinetics of topotecan in dogs following intravenous and oral administration [abstract]. Proc Am Assoc Cancer Res 1994; 35: 461
Davies BE, Minthorn EA, Dennis M, et al. The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog [abstract]. Eur J Cancer 1995; 31A: S192
Creemers GJ, Schellens JHM, Beijnen JH, et al. Bioavailability of oral topotecan, a new topoisomerase I inhibitor [abstract]. Proc Am Soc Clin Oncol 1994; 13: 132
Eckardt J, Burris H, Rizzo J, et al. A phase I safety and bioavailability study of oral topotecan [abstract]. Eur J Cancer 1995; 31A: S193
Schellens JHM, Eckardt JR, Verweij J, et al. Pharmacokinetics, clinical pharmacodynamics and safety of chronic oral topotecan in a phase I study [abstract]. Eur J Cancer 1995; 31A: S28
Cheng H, Jusko WJ. Pharmacokinetics of reversible metabolic systems. Biopharm Drug Dispos 1993; 14: 721–66
Grochow LB, Slichenmyer W, Rowinsky E, et al. Phase I clinical and pharmacologie study of topotecan in patients with hepatic or renal dysfunction [abstract]. Eighth NCI-EORTC Symposium on New Drugs in Cancer Chemotherapy; 1994 Mar 15–18; Amsterdam, 19
Slichenmyer W, Chen T-L, Donehower R, et al. Clinical pharmacology of topotecan in cancer patients with renal or hepatic dysfunction [abstract]. Proc Am Soc Clin Oncol 1994; 13: 142
Zamboni WC, Heideman RL, Meyer WH, et al. Pharmacokinetics (PK) of topotecan (TPT) in pediatric patients with normal and altered renal function [abstract]. Proc Am Soc Clin Oncol 1996; 15: 180
Burris III HA, Hanauske AR, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units. J Natl Cancer Inst 1992; 84: 1816–20
Houghton PJ, Cheshire PJ, Hallman II JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36: 393–403
Hochster H, Liebes L, Sorich J, et al. Increasing cleavable complex formation in peripheral blood lymphocytes with increasing topotecan infusion duration: a rationale for prolonged administration of camptothecins [abstract]. Sixth Conference on DNA Topoisomerases in Therapy. 1995 Sep 6–8; Amsterdam, 88
Hutson PR, Kim K, Johnson D, et al. Pharmacodynamic evaluation of the response of extensive stage small cell lung cancer to topotecan [abstract]. Proc Am Soc Clin Oncol 1995; 14: 460
Stewart CF, Baker SD, Furman WL, et al. Targeting plasma concentrations of topotecan during a 120-hr continuous infusion in children with relapsed acute leukemia [abstract]. Clin Pharmacol Ther 1995; 57: 176
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Herben, V.M.M., ten Bokkel Huinink, W.W. & Beijnen, J.H. Clinical Pharmacokinetics of Topotecan. Clin-Pharmacokinet 31, 85–102 (1996). https://doi.org/10.2165/00003088-199631020-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199631020-00001